Last reviewed · How we verify
NCT07497373: JL15003
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma
Phase 1 trial testing JL15003 Injection in Recurrent Glioblastoma Multiforme(GBM) in 17 participants. Completed in 23 May 2024.
23 May 2024
Quick facts
| Lead sponsor | Jecho Biopharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 16 November 2022 |
| Primary completion | 23 May 2024 |
| Estimated completion | 23 May 2024 |
| Sites | 3 locations across China |
Drugs / interventions tested
- JL15003 Injection
Conditions studied
- Recurrent Glioblastoma Multiforme(GBM) — all drugs for Recurrent Glioblastoma Multiforme(GBM) →
Sponsor
Jecho Biopharmaceuticals Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Recurrent Glioblastoma Multiforme(GBM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label, single-dose study consisting of a dose-escalation phase followed by a dose-expansion phase. Four dose levels are planned. Dose escalation will be conducted using an accelerated titration combined with a traditional "3+3" design. A total of 27 to 33 subjects are planned to be enrolled. The primary objective is to evaluate safety, with secondary objectives exploring efficacy and viral shedding. The study duration, from the first subject enrolled to the completion of the last subject's observation period (Day 57 visit), is estimated to be 1 to 2 years. A long-term survival follow-up period of approximately 15 years, or until all subjects are lost to follow-up or deceased, is planned. All data up to Day 57 will be used to support the initiation of a Phase II clinical trial. Any safety and efficacy data will be submitted to regulatory authorities on a rolling basis during the trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07497373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jecho Biopharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT07443228 — Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders · Phase 1 · not yet recruiting
- NCT07483970 — A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive · Phase 1 · not yet recruiting
- NCT07389577 — A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07497373 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jecho Biopharmaceuticals Co., Ltd.
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07497373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing